Product news

Share this article:
Canadian regulators have approved Novartis' Diovan (valsartan) to treat chronic heart failure in patients who cannot tolerate angiotensin-converting-enzyme (ACE)  inhibitors, a common type of heart failure therapy.   

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions